Indoco Remedies Receives 'Hold' Rating Upgrade

Indoco Remedies, a smallcap pharmaceutical company, has recently received a 'Hold' rating from MarketsMOJO. This upgrade is based on several factors that indicate a positive outlook for the company. One of the key reasons for the 'Hold' rating is the company's strong ability to service its debt. With a low Debt to EBITDA ratio of 1.40 times, Indoco Remedies has a solid financial standing. Additionally, the company has shown healthy long-term growth with its operating profit growing at an annual rate of 154.96%. From a technical standpoint, the stock is currently in a bullish range and has shown a positive trend since November 2023. This has resulted in a 5.59% return for investors. Furthermore, multiple technical indicators such as MACD, Bollinger Band, KST, and OBV are also bullish for the stock. In terms of valuation, Indoco Remedies has a fair valuation with a ROCE of 12.2 and an Enterprise value to Capital Employed ratio of 2.7. The stock is also trading at a discount compared to its average historical valuations. However, it is worth noting that the company has declared negative results for the last four consecutive quarters. This could be a cause for concern for investors. Additionally, the majority shareholders of the company are promoters. In the past year, while the stock has generated a negative return of -2.98%, its profits have also fallen by -29.9%. This underperformance is evident when compared to the market (BSE 500) which has generated a return of 16.72% in the same period. Overall, Indoco Remedies shows potential for growth with its strong financial standing and positive technical indicators. However, the recent negative results and underperformance in the market may be a cause for caution for investors.